

## DAFTAR PUSTAKA

- Anderson, G.W., Mariash, C.N., and Oppenheimer, J.H. 2000. Molecular actions of thyroid hormone. In, *Werner and Ingbar's The Thyroid*, 8<sup>th</sup> ed. (Braverman, L.E., and Utiger, R.D., eds.) Lippincot Williams & Wilkins, New York, pp.174-195.
- Baran, D.T. 2000. *The skeletal system in thyrotoxicosis*. In, *Werner and Ingbar's the thyroid*, 8<sup>th</sup> ed, New York, pp.659-666.
- Batari RM, Hendromartono. 2006. *Endokrin-metabolik*. Surabaya: AUP pp1-8
- Benker, G., Vitti, P., et al. 1995. Response to methimazole in Grave's disease. The European Multicenter Study Group. *Clinic Endocrinal. (oxf)*, 43:257-263.
- Berkat, H. 2012. *hubungan hipertiroid overt dan hipertiroid subklinis dengan gangguankognitif di rsup dr sardjito Yogyakarta*. Yogyakarta : UGM, pp 1-7.
- Brams, E.O. 2005. *Thyroid Disease*. USA: Humana Press Inc. pp.12-61.
- Braverman, L.E., Eber, O., and Langsteger, W. 1994. *Heart and Thyroid*. Blackwell-MZV, Vienna.
- Carrasco, N. 2000. Thyroid iodine transport: the Na<sup>+</sup>/I<sup>-</sup> symporter (NIS). In, *Werner and Ingbar's The Thyroid*, 8<sup>th</sup> ed. (Braverman, L.E., and Utiger, R.D., eds.) Lippincot Williams & Wilkins, New York, pp.52-60
- Cheng SY, Leonard JL, Davis PJ. 2010. Molecular aspects of thyroid hormone actions. *Endocrinal Review*. 31:139-70
- Cooper DS. 1999. The side effects of antithyroid drugs. *Endocrinologist*, pp 457-76.
- Cooper DS. 2005. *Drug Therapy Antithyroid Drugs*. N Eng J Med 352:905-17.

- Dalan R, Leow MK. Cardiovascular collapse associated with beta-blockade in thyroid storm. *Exp clin Endocrinol Diabetes*; 115:39-26
- Dipiro, JT.2008.*Pharmacotherapy a pathophysiologic approach*. USA:the Mc-Graw-Hill Companies.
- Dunn,J.T.,and Dunn, A.D. 2000.Thyroglobulin:chemistry, biosynthesis, and proteolysis. In, *Werner and Ingbar's The Thyroid*, 8<sup>th</sup> ed. (Braverman, L.E., and Utiger, R.D.,eds.) Lippincot Williams & Wilkins, New York,pp 91-104.
- Eng,P.H.,Cardona, G.R.,et al.1999.Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. *Endocrinology*,140:3404-3410.
- Fauci's,DR.,Longo,DR.2008.*Harrison's principle of internal medicine 17<sup>th</sup> edition*.USA: The McGraww-Hill Companies, part 15<sup>th</sup> .335.
- Fitzgerald PA.2005. In: Tierny LM, McPhee SJ, Papadakis MA, eds. Current medical diagnosis and treatment. Endocrinology. 44th ed. New York: McGraw-Hill,pp.1102–10.
- Ganong, William F.,2002, *Buku Ajar Fisiologi Kedokteran*, Jakarta:EGC, pp.305-319.
- Gilman,AG.2010.*Dasar Farmakologi Terapi*.Edisi 10.Vol.4.Jakarta:EGC, pp.1534-1560.
- Gregory, AB.2010.*Thyroid Function Testing*.New York: Springer, pp.1-16.
- Greenspan FS. 2004. *The thyroid gland. Basic & Clinical Endocrinology 7<sup>th</sup>ed*. The McGraw-Hill Companies, editors Greenspan FS, Gardner DG, pp 260-270.
- Greenstein.B & Wood.D.2010.*At a Glance Sistem Endokrin edisi kedua*.Jakarta:EMS.
- Griffen JE.2004. *The thyroid*. In: *Griffin JE, Ojeda SR, eds. Endocrine Physiology*. New York: Oxford University Press:294–318.
- Imseis, R.E., Vanmiddlesworth, L.,et al.1998.Pretreatment with propilthiouracil but not methimazole reduces the therapeutic

- efficacy of iodine-131 in hyperthyroidism. *Journal Clinic Metabolism*, 83:685-687.
- Kallner G, Ljunggren JG, Tryselius M.1978. The effect of propranolol on serum levels of T4, T3 and reverse-T3 in hyperthyroidism. *Acta Med Scand* ;204: 35-7
- Kane LA, Gharib H.2003.*Thyroid testing: a clinical approach*. In: *Braverman LE, ed. Diseases of the Thyroid*, 2nd ed. Totowa: Humana Press.
- Katzung,BG.2010.*Farmakologi Dasar & Klinik*.Jakarta:EGC, pp 637-653.
- Klein I, Ojamaa K.2001. Thyroid hormone and the cardiovascular system.*The New England Journal of Medicine*.344:501-9.
- Klein RZ, et al.1991. Subclinical Hypothyroidism.*Thyroid International*,3:3-8.
- Maugendre, D.,Gatel, A.,et al.1999. Antithyroid drugs and Grave's disease-prospective randomized assessment of long-term treatment.*Clinic Endocrinology (Oxf)*,50:127-132.
- Marchant B, Brownlie BEW, McKay Hart D, et al.1997.The Placental transfer of Propylthiouracil, Methimazole and Carbimazole. *J Clin Endocrinol Metab* 45:1187
- McAuley, D. Pharm.D., 2013. *Common Laboratory LAB Values*
- McPhee, S.J., 2006. Thyroid Disease. *Pathophysiology of Disease*. California: McGraw Hill's Access Medicine
- Mitsiades N, Poulaki V, Tseleni-Balafouta, S, Chrousos GP, Koutras DA.2000.Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves'disease. *Thyroid*.10:527-32.
- Momotani N, Noh JY, Ishikawa N, et al.1997.Effects of Propylthiouracil and methimazole on fetal thyroid status in mothers with Grave's hyperthyroidism.*J Clin Endocrinal Metab* 82:3633

- Nayak B, Hodak SP.2007. Hyperthyroidism.*Endocrinol Metabolism Clinic North Am*, 36:617-656.
- Neal JM.2000. Thyroid gland. In: *Neal JM, ed. Basic Endocrinology: An Interactive Approach*. Malden,MA: Blackwell Science:51–87.
- Neal, JM.2006.*At a Glance Farmakologi Medis*.edisi kelima.Jakarta:EMS.
- Nilsson OR, Karlberg BE, Kagedal B et al.1979. Non-selective and selective beta-1 adrenoreceptor blocking agents in the treatment of hyperthyroidism. *Acta Med Scand*; 206:21-5
- Price AS.2005.*Patofisiologi Konsep Klinis Proses-Proses Penyakit*. Vol.2. Jakarta : EGC.
- Rittmaster, R.S., Abbott,E.C.,et al.1998.Effect of methimazole, with or without L-thyroxine, on remission rates in Grave’s disease. *Journal Clinic Endocrinology Metabolic*, 83:814-818.
- Ross DS. 1994.Hyperthyroidism,thyroid hormone therapy, and bone. *Thyroid*.4:319-26
- Ross DS.2005. Sublinical Hyperthyroidism. In:*2<sup>nd</sup> Joint SPED/AACE International Endocrine Clinical Update and 28<sup>th</sup> SPED Post Graduate Diabetes Course*. San Juan, Puerto Rico, pp66-76
- Ross DS.2011.Radioiodine Therapy for Hyperthyroidism.*The New England Journal of Medicine*;364:542-550.
- Roti.,E.,and Vagenakins, A.G.2000. Effects of excess iodine: clinical aspects. In, ). In, *Werner and Ingbar’s The Thyroid*, 8<sup>th</sup> ed. (Braverman, L.E., and Utiger, R.D.,eds.) Lippincot Williams & Wilkins, New York, pp.316-332.
- Shargel L, Mutrick AH, Souney P and Swanson L.2007.*Comprehensive Pharmacy Review*, NewYork:Wolters Kluwer, pp1179-1021
- Silva JE, Bianco SDC.2008.Thyroid-adrenergic interactions: physiological and clinical implications. *Thyroid*. 18:157-65
- Smerdely, P., Pitsiavas, V., and boyages, S.C.1993.Evidence that the inhibitory effects of iodide on thyroid cell proliferation are due to

- arrest of the cell cycle at G0G1 and G2M phases. *Endocrinology*, 133:2881-2888.
- Soloman, B., Glinoe, D., Lagasse, R., and Wartofsky, L. 1990. Current trends in the management of Grave's disease. *Journal Clin Endocrinology Metabolic*, 70:1518-1524.
- Spitzweg C, Heufelder A, Morris JC. 2000. Thyroid iodine transport. *Thyroid*; 10:321-330.
- Tallstedt L, Lundell G, Topping O, et al. 1992. Occurrence of ophthalmopathy after treatment for Grave's hyperthyroidism. *The New England Journal of Medicine*; 326:1733-8.
- Taugog, A. 2000. Hormone synthesis: thyroid iodine metabolism. In, *Werner and Ingbar's The Thyroid, 8<sup>th</sup> ed.* (Braverman, L.E., and Utiger, R.D., eds) Lippincott Williams & Wilkins, New York, pp.61-84.
- Topping, O., Tallstedt, L., et al. 1996. Grave's hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid study group. *Journal Clin Endocrinology Metabolic.*, 81:2986-2993.
- Volpe R. 2001. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. *Curr Pharm Des* 7:451-60.
- Warren, R.H. 2008. *Thyroid Disorders with Cutaneous Manifestations*. London : Springer-Verlag London Limited, pp 13-83.
- Wartofsky L, Glinoe D, Solomon B, et al. 1991. Differences and similarities in the diagnosis and treatment of Grave's disease in Europe, Japan and United States. *Thyroid*. 1:129-35.
- Weetman AP. 2000. Grave's disease. *The New England Journal of Medicine*. 343: 1236-124.